Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
For researchers exploring other metabolic compound categories, related overviews are available on MOTS-c research and peptide for longevity research
Quick and painless Delivered as promised
Patients ( N = 148) with type 2 diabetes with inadequate glycemic control on metformin (median duration of disease of 6.7 years, mean baseline HbA 1c 5557 mmol/mol [7.27.4%]) were randomised to receive lixisenatide (initiated at 10 g OD for 2 weeks followed by 20 g OD), or liraglutide (started at 0.6 mg and titrated up to 1.8 mg OD)
Perform Better
What types of IV therapy do we offer
US$ 21.73
US$ 25.34
US$ 25.98
US$ 22.95
US$ 27.71
